iron chelating agents การใช้

Clinical trials in the MDS are ongoing with iron chelating agents to address the question of whether iron chelation alters the natural history of patients with MDS who are transfusion dependent.
In 1987, the first use of a clinically effective oral iron chelating agent, deferiprone, was reported from his group including George Kontoghioghes and Beatrix Wonke and in 1998, the first use of combination iron chelation therapy.
Current research focuses on the future use of high dose pantothenate, the PANK2 enzyme substrate, in possibly alleviating symptoms as well as the further development of iron chelating agents that may be better aimed at reaching the central nervous system and working to better remove excess iron from the individual s system.